Cancer drug dasatinib tested to shrink hidden HIV reservoirs
Disease control
Completed
This phase 2 trial tested whether a low dose of dasatinib, a cancer drug, is safe and can reduce the hidden HIV reservoir and inflammation in people with HIV who are already on effective antiretroviral therapy. Sixty participants took either dasatinib or a placebo daily for 24 we…
Phase: PHASE2 • Sponsor: Fundació Institut Germans Trias i Pujol • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC